Resources

VillageHealth has no financial arrangements with other organizations to advertise, market or promote products or services.
VillageHealth does not advertise, market or promote specific products or services to patients or providers.

Statement of Practitioner Support - Provider Rights and Responsibilities

VillageHealth is committed to partnering with healthcare practitioners to deliver high quality care to plan members. As part of this commitment, our goal is to ensure open, timely communication with practitioners. Although specific areas of support are outlined below, practitioners can contact the VillageHealth Medical Director, VillageHealth Nurse and other VillageHealth staff at 1-800-767-0063 about any issue. You can also visit us on the web at www.villagehealthdm.com.

Program Information. During the implementation process, VillageHealth will provide information about its programs and services, assigned staff, staff qualifications, and contractual relationships. Following the implementation process, this information will be available by request at any time.
Program Participation. Unless otherwise stated in their agreement with the health plan, practitioners may opt out of program participation.
Coordination of patient care. VillageHealth will make sure the practitioner knows which VillageHealth staff is primarily responsible for day-to-day care coordination of the practitioner’s patients. VillagheHealth will send the practitioner a written care plan for each patient followed by updates regarding specific issues encountered during implementation of the plan. The practitioner will also receive regular reports showing patient outcomes compared with regional and national benchmarks.
Contact information for primary VillageHealth support staff. VillageHealth will provide the practitioner with the contact information for the nurse responsible for managing and communicating with the practitioner’s patients. VillageHealth nursing staff can be reached 24 hours per day, 7 days per week.
Decision making support. VillageHealth will actively support the practitioner in making decisions interactively with their patients. This includes provision of a written care plan, episodic issues reports, and quarterly outcomes reports to the provider.
Professional conduct. VillageHealth employees provide courteous service and respectful treatment for practitioners, their staff, and their patients.
Complaint resolution. VillageHealth will provide clear, timely resolution of any practitioner issues. Practitioners can raise issues either by calling 1-800-767-0063 or by addressing correspondence to the address below:

             VillageHealth Disease Management
             Three Hawthorn Parkway, Suite 410
              Vernon Hills, IL 60061

VillageHealth Disease Management

Clinical Practice Guideline/Clinical Practice Recommendation

SUMMARY TABLE

ITEM #	TITLE	CKD Stage 3-5 not on dialysis	CKD Stage 5 on dialysis
1.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification
2.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access
3.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.
4.	National Kidney Foundation. KDOQI^TM Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target* (excluding CPR 2.1.2)*
5.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines for Nutrition in Chronic Renal Failure.
6.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease
7.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease (excluding CPG 1.4, 3.2, & 6.5)
8.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease
9.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
10.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease(excluding CPG 2)
11.	Renal Physicians Association Clinical Practice Guideline #2 *Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis, February 2000*
12.	Renal Physicians Association Clinical Practice Guideline #3; *Appropriate Patient Preparation for Renal Replacement Therapy*
13.	Advisory Committee on Immunization Practices. Recommended adult immunization schedule
14.	FDA EPOGEN® (Epoetin alfa) FOR INJECTION package insert
15.	Suma Dronovalli, Basil Burney, George Bakris. Glycemic Control and Cardiovascular Disease in Chronic Kidney Disease
16.	KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

DETAILED TABLE

1.	National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39:S1-S000, 2002 (suppl 1) http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm
Stages 3-5 (not on dialysis)	Figures Tables Acronyms and abbreviations K/DOQI advisory board members Work group and evidence review team membership and support group Foreword Part 1. Executive Summary Part 2. Background Part 3. Chronic kidney disease as a public health problem Part 4. Definition and classification of stages of chronic kidney disease Guideline 1. Definition and Stages of Chronic Kidney Disease Guideline 2. Evaluation and Treatment Guideline 3. Individuals at Increased Risk of Chronic Kidney Disease Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease Guideline 4. Estimation of GFR Guideline 5. Assessment of Proteinuria Guideline 6. Markers of Chronic Kidney Disease Other Than Proteinuria Part 6. Association of level of GFR with complications in adults Guideline 7. Association of Level of GFR With Hypertension Guideline 8. Association of Level of GFR With Anemia Guideline 9. Association of Level of GFR With Nutritional Status Guideline 10. Association of Level of GFR With Bone Disease and Disorders of Calcium and Phosphorus Metabolism Guideline 11. Association of Level of GFR With Neuropathy Guideline 12. Association of Level of GFR With Indices of Functioning and Well-Being Part 7. Stratification of risk for progression of kidney disease and development of cardiovascular disease Guideline 13. Factors Associated With Loss of Kidney Function in Chronic Kidney Disease Guideline 14. Association of Chronic Kidney Disease With Diabetic Complications Guideline 15. Association of Chronic Kidney Disease With Cardiovascular Disease Part 8. Recommendations for clinical performance measures Part 9. Approach to chronic kidney disease using these guidelines Part 10. Appendices Appendix 1. Methods for Review of Articles Appendix 2. Kidney Function and Associated Conditions in the United States: Methods and Findings From the Third National Health and Nutrition Examination Survey (1988 to 1994) Appendix 3. Methodological Aspects of Evaluating Equations to Predict GFR and Calculations Using 24-Hour Urine Samples Part 11. Work group members Part 12. Acknowledgements Bibliography Disclaimer
2.	National Kidney Foundation. *KDOQI^TM* Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. Am J Kidney Dis 48:S1-S322, 2006 (suppl 1). http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm**
Stage 5 (on dialysis)	CLINICAL PRACTICE GUIDELINES FOR HEMODIALYSIS ADEQUACY, UPDATE 2006 Hemodialysis Adequacy 2006 Work Group Membership Tables and Figures Abbreviations and Acronyms Foreword Introduction I: Clinical Practice Guidelines for Hemodialysis Adequacy Guideline 1. Initiation of Dialysis Guideline 2. Methods for Measuring and Expressing the Hemodialysis Dose Guideline 3. Methods for Postdialysis Blood Sampling Guideline 4. Minimally Adequate Hemodialysis Guideline 5. Control of Volume and Blood Pressure Guideline 6. Preservation of Residual Kidney Function Guideline 7. Quality Improvement Programs Guideline 8. Pediatric Hemodialysis Prescription and Adequacy II: Clinical Practice Recommendations for Hemodialysis Adequacy Clinical Practice Recommendation for Guideline 1: Initiation of Dialysis Clinical Practice Recommendations for Guideline 2: Methods for Measuring and Expressing the Hemodialysis Dose Clinical Practice Recommendations for Guideline 4: Minimally Adequate Hemodialysis Clinical Practice Recommendation 5: Dialyzer Membranes and Reuse Clinical Practice Recommendations for Guideline 6: Preservation of Residual Kidney Function III: Research Recommendations Appendix. Methods for Adding Residual Clearance to Hemodialyzer Clearance Work Group Biographies References Abbreviations and Acronyms Appendix 1. Methods for Evaluating Evidence Appendix 2. Medline Search Strategies Disclaimer
Stage 5 (on dialysis)	CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY, UPDATE 2006 Peritoneal Dialysis Adequacy 2006 Work Group Membership Tables Abbreviations and Acronyms Foreword Introduction I: Clinical Practice Guidelines for Peritoneal Dialysis Adequacy Guideline 1. Initiation of Dialysis Guideline 2. Peritoneal Dialysis Solute Clearance Targets and Measurements Guideline 3. Preservation of Residual Kidney Function Guideline 4. Maintenance of Euvolemia Guideline 5. Quality Improvement Programs Guideline 6. Pediatric Peritoneal Dialysis II. Clinical Practice Recommendations for Peritoneal Dialysis Adequacy Clinical Practice Recommendation for Guideline 1: Initiation of Dialysis Clinical Practice Recommendations for Guideline 2: Peritoneal Dialysis Prescription Targets and Measurements Clinical Practice Recommendations 3: Recommended Laboratory Measurements for Peritoneal Membrane Function and Ultrafiltration Volume Clinical Practice Recommendations 4: Writing the Peritoneal Dialysis Prescription Clinical Practice Recommendations for Guideline 6: Pediatric Peritoneal Dialysis III. Research Recommendations Work Group Biographies References Abbreviations and Acronyms Appendix 1. Methods for Evaluating Evidence Appendix 2. Medline Search Strategies Disclaimer
All Stages	CLINICAL PRACTICE GUIDELINES FOR VASCULAR ACCESS, UPDATE 2006 Vascular Access 2006 Work Group Membership Tables and Figures Abbreviations and Acronyms Glossary Foreword Introduction I. Clinical Practice Guidelines for Vascular Access Guideline 1. Patient Preparation for Permanent Hemodialysis Access Guideline 2. Selection and Placement of Hemodialysis Access Guideline 3. Cannulation of Fistulae and Grafts and Accession of Hemodialysis Catheters and Port Catheter Systems Guideline 4. Detection of Access Dysfunction: Monitoring, Surveillance, and Diagnostic Testing Guideline 5. Treatment of Fistula Complications Guideline 6. Treatment of Arteriovenous Graft Complications Guideline 7. Prevention and Treatment of Catheter and Port Complications Guideline 8. Clinical Outcome Goals II. Clinical Practice Recommendations for Vascular Access Clinical Practice Recommendations for Guideline 1: Patient Preparation for Permanent Hemodialysis Access Clinical Practice Recommendations for Guideline 2: Selection and Placement of Hemodialysis Access Clinical Practice Recommendations for Guideline 3: Cannulation of Fistulae and Grafts and Accession of Dialysis Catheters and Ports Clinical Practice Recommendations for Guideline 4: Detection of Access Dysfunction: Monitoring, Surveillance, and Diagnostic Testing Clinical Practice Recommendations for Guideline 5: Treatment of Fistula Complications Clinical Practice Recommendations for Guideline 7: Prevention and Treatment of Catheter and Port Complications Clinical Practice Recommendation 8: Vascular Access in Pediatric Patients III. Research Recommendations Work Group Biographies References Abbreviations and Acronyms Appendix 1. Methods for Evaluating Evidence Appendix 2. Medline Search Strategies Disclaimer
3.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47:S1-S146, 2006 (suppl 3). http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm
All Stages	Tables Figures Abbreviations and Acronyms Work Group Membership KDOQI Advisory Board Members Foreword I: Executive Summary II: Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults 1.1. Identifying Patients and Initiating Evaluation 1.2. Evaluation of Anemia in CKD 2.1. Hb Range 3.1. Using ESAs 3.2. Using Iron Agents 3.3. Using Pharmacological and Nonpharmacological Adjuvants to ESA Treatment in HD-CKD 3.4. Transfusion Therapy 3.5. Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb III: Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Children 1.1. Identifying Patients and Initiating Evaluation 1.2. Evaluation of Anemia in CKD 2.1. Hb Range 3.1. Using ESAs 3.2. Using Iron Agents 3.3. Using Pharmacological and Nonpharmacological Adjuvants to ESA Treatment in HD-CKD 3.4. Transfusion Therapy 3.5. Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb Level IV: Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Transplant Recipients V: Appendix 1: Methods of Evidence Review and Synthesis Work Group Biographies Acknowledgments References Disclaimer
4.	KDOQI^TM Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target http://www.kidney.org/professionals/kdoqi/guidelines_anemiaUP/index.htm
All Stages	Work Group Membership K/DOQI™ Advisory Board Members Tables and Figures CPG and CPR 2.1 Hemoglobin Target Rationale for CPR 2.1.1 Rationale for CPR 2.1.2 – this CPR is not adopted by VillageHealth DM Rationale for CPG 2.1.3 CPR for Pediatrics 2.1 Hemoglobin Target Anemia Update Methods Appendix 1. Comparison of FDA-Approved Prescribing Information for Epoetin Alfa and KDOQI Anemia Guidelines Biographical and Disclosure Information References
5.	National Kidney Foundation. KDOQI^TM Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. American Journal of Kidney Diseases, June 2000 http://www.kidney.org/professionals/KDOQI/guidelines_updates/doqi_nut.html
All Stages	I. ADULT GUIDELINES A. Maintenance Dialysis 1. Evaluation of Protein-Energy Nutritional Status Guideline 1. Use of Panels of Nutritional Measures Guideline 2. Panels of Nutritional Measures for Maintenance Dialysis Patients Guideline 3. Serum Albumin Guideline 4. Serum Prealbumin Guideline 5. Serum Creatinine and the Creatinine Index Guideline 6. Serum Cholesterol Guideline 7. Dietary Interviews and Diaries Guideline 8. Protein Equivalent of Total Nitrogen Appearance (PNA) Guideline 9. Subjective Global Nutritional Assessment (SGA) Guideline 10. Anthropometry Guideline 11. Dual Energy X-Ray Absorptiometry (DXA) Guideline 12. Adjusted Edema-Free Body Weight (aBW_ef) 2. Management of Acid-Base Status Guideline 13. Measurement of Serum Bicarbonate Guideline 14. Treatment of Low Serum Bicarbonate 3. Management of Protein and Energy Intake Guideline 15. Dietary Protein Intake (DPI) in Maintenance Hemodialysis (MHD) Guideline 16. Dietary Protein Intake (DPI) for Chronic Peritoneal Dialysis (CPD) Guideline 17. Daily Energy Intake for Maintenance Dialysis Patients 4. Nutritional Counseling and Follow-Up Guideline 18. Intensive Nutritional Counseling With Maintenance Dialysis (MD) Guideline 19. Indications for Nutritional Support Guideline20. Protein Intake During Acute Illness Guideline 21. Energy Intake During Acute Illness 5. Carnitine Guideline 22. L-Carnitine for Maintenance Dialysis Patients B. Advanced Chronic Renal Failure Without Dialysis Guideline 23. Panels of Nutritional Measures for Nondialyzed Patients Guideline 24. Dietary Protein Intake for Nondialyzed Patients Guideline 25. Dietary Energy Intake (DEI) for Nondialyzed Patients Guideline 26. Intensive Nutritional Counseling for Chronic Renal Failure (CRF) Guideline 27. Indications for Renal Replacement Therapy C. Appendices (Adult Guidelines) Appendix I. Methods for Measuring Serum Albumin Appendix II. Methods for Calculation and Use of the Creatinine Index Appendix III. Dietary Interviews and Diaries Appendix IV. Role of the Renal Dietitian Appendix V. Rationale and Methods for the Determination of the Protein Equivalent of Nitrogen Appearance (PNA) Appendix VI. Methods for Performing Subjective Global Assessment Appendix VII. Methods for Performing Anthropometry and Calculating Body Measurements and Reference Tables Appendix VIII. Serum Transferrin and Bioelectrical Impedance Analysis Appendix IX. Estimation of Glomerular Filtration Rate Appendix X. Potential Uses for L-Carnitine in Maintenance Dialysis Patients D. References (Adult Guidelines) E. Index of Equations and Tables (Adult Guidelines)
6.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41:S1-S92, 2003 (suppl 3) http://www.kidney.org/professionals/kdoqi/guidelines_lipids/index.htm
All Stages	Tables Figures Acronyms and Abbreviations Work Group Membership K/DOQI Advisory Board Members Foreword Abstract Part 1. Introduction The Rational for These Guidelines Target Population Scope Intended Users Anticipated Updates Methods Guidelines, Evidence, and Research Recommendations Part 2. Assessment of Dyslipidemias Guideline 1. Guideline 2. Guideline 3. Part 3. Treating Dyslipidemias Guideline 4. Guideline 5. Part 4. Research Recommendations Part 5. Appendices Appendix 1. Methods for Review of Articles Aims Overview of the Process Appendix 2. Therapeutic Lifestyle Change: Diet for Patients with Chronic Kidney Disease Biographical Sketches of Work Group Members Acknowledgments References Disclaimer
7.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S202, 2003 (suppl 3) http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm
All Stages	Tables Figures Algorithms Acronyms and Abbreviations Work Group Membership Foreword Introduction Guideline Statements Background Methods for Analysis of Literature Clinical Practice Guidelines Guideline 1. Evaluation of Calcium and Phosphorus Metabolism – CPG 1.4 is not adopted by VillageHealth DM due to new findings by KDIGO Guideline 2. Assessment of Bone Disease Associated With CKD Guideline 3. Evaluation of Serum Phosphorus Levels – CPG 3.2 is not adopted by VillageHealth DM due to new findings by KDIGO Guideline 4. Restriction of Dietary Phosphorus in Patients With CKD Guideline 5. Use of Phosphate Binders in CKD Guideline 6. Serum Calcium and Calcium-Phosphorus Product – CPG 6.5 is not adopted by VillageHealth DM due to new findings by KDIGO Guideline 7. Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients Guideline 8. Vitamin D Therapy in CKD Patients Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5) Guideline 9. Dialysate Calcium Concentrations Guideline 10. ß₂-Microglobulin Amyloidosis Guideline 11. Aluminum Overload and Toxicity in CKD Guideline 12. Treatment of Aluminum Toxicity Guideline 13. Treatment of Bone Disease in CKD Guideline 13A. Hyperparathyroid (High-Turnover) and Mixed (High-Turnover With Mineralization Defect) Bone Disease Guideline 13B. Osteomalacia Guideline 13C. Adynamic Bone Disease Guideline 14. Parathyroidectomy in Patients With CKD Guideline 15. Metabolic Acidosis Guideline 16. Bone Disease in the Kidney Transplant Recipient The Overall Approach to the Management of Bone Metabolism and Disease in CKD Patients Biographical Sketches of Work Group Members References Complete Bibliography From Evidence Reports Disclaimer
8.	National Kidney Foundation. K/DOQI^TM Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43:S1-S290, 2004 (suppl 1) http://www.kidney.org/professionals/kdoqi/guidelines_bp/index.htm
All Stages	Tables - Tip Figures - Tip Acronyms and Abbreviations Work Group Membership and Evidence Review Team K/DOQI Advisory Board Members Foreword Executive Summary Background Clinical Practice Guidelines *Guideline 1.* Goals of Antihypertensive Therapy in CKD *Guideline 2.* Evaluation of Patients With CKD or Hypertension Guideline 3. Measurement of Blood Pressure in Adults *Guideline 4.* Evaluation for Renal Artery Disease Guideline 5. Education on Self-Management Behavior Guideline 6. Dietary and Other Therapeutic Lifestyle Changes in Adults *Guideline 7.* Pharmacological Therapy: Use of Antihypertensive Agents in CKD *Guideline 8.* Pharmacological Therapy: Diabetic Kidney Disease Guideline 9. Pharmacological Therapy: Nondiabetic Kidney Disease Guideline 10. Pharmacological Therapy: Kidney Disease in the Kidney Transplant Recipient Guideline 11. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD Guideline 12. Use of Diuretics in CKD *Guideline 13.* Special Considerations in Children Recommendations for Clinical Performance Measures Appendices *Appendix 1:* Methods Used for Guideline Development *Appendix 2:* MEDLINE Search Strategies *Appendix 3:* Technical Report on Ambulatory Blood Pressure Monitoring in CKD Work Group Biographies Acknowledgments References K/DOQI Disclaimer
9.	National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45:S1-S154, 2005 (suppl 3) http://www.kidney.org/professionals/kdoqi/guidelines_cvd/index.htm
Stage 5 (on dialysis)	Tables Figures Acronyms and abbreviations Work group members K/DOQI advisory board members Foreword Overview of epidemiology of cardiovascular disease Overview of epidemiology of cardiovascular disease in children Section I. Guidelines on evaluation and management of cardiovascular diseases Guideline 1: Evaluation of Cardiovascular Disease in Adult and Pediatric Patients Guideline 2: Coronary Artery Disease Guideline 3: Acute Coronary Syndromes Guideline 4: Chronic Coronary Artery Disease Guideline 5: Valvular Heart Disease Guideline 6: Cardiomyopathy (Systolic or Diastolic Dysfunction) Guideline 7: Dysrhythmia Guideline 8: External Defibrillation Guideline 9: Cerebrovascular Disease Guideline 10: Peripheral Vascular Disease Section II. Guidelines on management of cardiovascular risk factors Guideline 11: Diabetes Guideline 12: Blood Pressure Guideline 13: Dyslipidemia Guideline 14: Smoking, Physical Activity, and Psychological Factors Guideline 15: Anemia Guideline 16: Arterial Stiffness, Vascular and Valvular Calcification, Calcium, Phosphorus and PTH Section III. State of the science: novel and controversial topics in cardiovascular diseases Intradialytic Hypotension Biomarkers Troponin Inflammation Oxidative Stress Nutritional and Metabolic Factors Body Weight and Management Omega-3 Fatty Acids Homocysteine Lipoprotein(a) and Apolipoprotein(a) Polymorphism Malnutrition Risk Stratification Overview of Risk Stratification Family History and Genetics Menopause Preventive Foot Care in Diabetes Aspirin Methods for review of article Work group biographies Acknowledgment References Disclaimer
10.	National Kidney Foundation. KDOQI™ Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S1-S180, 2007 (suppl 2) http://www.kidney.org/professionals/kdoqi/guideline_diabetes/
All Stages	Tables Figures Acronyms and Abbreviations Work Group Membership KDOQI Advisory Board Members Foreword Disclaimer EXECUTIVE SUMMARY Executive Summary CLINICAL PRACTICE GUIDELINES Background Guideline 1: Screening and Diagnosis of Diabetic Kidney Disease Guideline 2: Management of Hyperglycemia and General Diabetes Care in Chronic Kidney Disease *– this CPG is not adopted by VillageHealth DM* Guideline 3: Management of Hypertension in Diabetes and Chronic Kidney Disease Guideline 4: Management of Dyslipidemia in Diabetes and Chronic Kidney Disease Guideline 5: Nutritional Management in Diabetes and Chronic Kidney Disease CLINICAL PRACTICE RECOMMENDATIONS Clinical Practice Recommendation 1: Management of Albuminuria in Normotensive Patients With Diabetes and Albuminuria as a Surrogate Marker Clinical Practice Recommendation 2: Multifaceted Approach to Intervention in Diabetes and Chronic Kidney Disease Clinical Practice Recommendation 3: Diabetes and Chronic Kidney Disease in Special Populations Clinical Practice Recommendation 4: Behavioral Self-Management in Diabetes and Chronic Kidney Disease RESEARCH RECOMMENDATIONS Research Recommendation APPENDICES Appendix 1: Nutritional Management of Diabetes and Chronic Kidney Disease Appendix 2: Methods for Evaluating Evidence WORK GROUP BIOGRAPHIES, ACKNOWLEGMENTS, & REFERENCES Work Group Biographies Acknowledgments References
11.	Renal Physicians Association Clinical Practice Guideline #2 *Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis, February 2000*
Stage 5 (on dialysis)	RPA Guideline #2 You must have access to VillageHealth Intranet to use this link
12.	Renal Physicians Association Clinical Practice Guideline #3; Appropriate Patient Preparation for Renal Replacement Therapy, October 2002
Stages 3-5 (not on dialysis)	Sections: *Counseling and Rehabilitation, page 55* *Timing of Initiation for RRT, page 63* *RPA Guideline #3* You must have access to VillageHealth Intranet to use this link
13.	Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med. 2007; 147:725-9.
All Stages	ACIP You must have access to VillageHealth Intranet to use this link
14.	FDA EPOGEN® (Epoetin alfa) FOR INJECTION. EPOGEN® package insert, FDA Approved: 11-19-08
All Stages	EPOGEN You must have access to VillageHealth Intranet to use this link
15.	Suma Dronovalli, Basil Burney, George Bakris Glycemic Control and Cardiovascular Disease in Chronic Kidney Disease. Current Diabetes Reports, Vol. 9, No. 3 (1 June 2009), pp. 243-248.
All Stages	Glycemic You must have access to VillageHealth Intranet to use this link
16.	Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney International 2009; 76 (Suppl 113): S1–S130.
All Stages	Tables and figures Disclaimer Work Group membership KDIGO Board Members Abbreviations and acronyms Reference Keys Abstract Foreword Guideline 1: Introduction and definition of CKD–MBD and the development of the guideline statements Guideline 2: Methodological approach Guideline 3.1: Diagnosis of CKD–MBD: biochemical abnormalities Guideline 3.2: Diagnosis of CKD–MBD: bone Guideline 3.3: Diagnosis of CKD–MBD: vascular calcification Guideline 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium Guideline 4.2: Treatment of abnormal PTH levels in CKD–MBD Guideline 4.3: Treatment of bone with bisphosphonates, other osteoporosismedications, and growth hormone Guideline 5: Evaluation and treatment of kidney transplant bone disease Guideline 6: Summary and research recommendations Biographic and disclosure information Acknowledgments References